Sigma Investment Counselors Inc. Sells 576 Shares of Stryker Corporation (SYK)
Sigma Investment Counselors Inc. lessened its stake in shares of Stryker Corporation (NYSE:SYK) by 1.1% in the fourth quarter, Holdings Channel reports. The fund owned 51,153 shares of the medical technology company’s stock after selling 576 shares during the quarter. Stryker comprises about 1.1% of Sigma Investment Counselors Inc.’s holdings, making the stock its 15th biggest position. Sigma Investment Counselors Inc.’s holdings in Stryker were worth $7,921,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in the company. Sawyer & Company Inc purchased a new stake in shares of Stryker in the fourth quarter valued at $125,000. Sit Investment Associates Inc. lifted its holdings in shares of Stryker by 114.3% in the fourth quarter. Sit Investment Associates Inc. now owns 825 shares of the medical technology company’s stock valued at $128,000 after purchasing an additional 440 shares in the last quarter. San Francisco Sentry Investment Group CA lifted its holdings in shares of Stryker by 47.8% in the third quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock valued at $143,000 after purchasing an additional 325 shares in the last quarter. Oak Point Wealth Management purchased a new stake in shares of Stryker in the fourth quarter valued at $145,000. Finally, Dubuque Bank & Trust Co. purchased a new stake in shares of Stryker in the fourth quarter valued at $164,000. Institutional investors own 74.71% of the company’s stock.
A number of research firms have recently issued reports on SYK. Oppenheimer restated a “hold” rating and issued a $165.00 target price on shares of Stryker in a report on Thursday, February 1st. Citigroup restated a “market perform” rating and issued a $165.00 target price (up previously from $156.00) on shares of Stryker in a report on Thursday, February 1st. They noted that the move was a valuation call. Guggenheim restated a “buy” rating on shares of Stryker in a report on Wednesday, January 31st. Piper Jaffray Companies restated a “buy” rating and issued a $170.00 target price on shares of Stryker in a report on Wednesday, January 31st. Finally, Cantor Fitzgerald restated a “hold” rating and issued a $163.00 target price on shares of Stryker in a report on Tuesday, January 30th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $162.50.
Shares of Stryker Corporation (NYSE SYK) opened at $153.66 on Tuesday. The company has a current ratio of 2.29, a quick ratio of 1.59 and a debt-to-equity ratio of 0.66. Stryker Corporation has a 1-year low of $123.34 and a 1-year high of $170.00. The stock has a market capitalization of $56,653.36, a price-to-earnings ratio of 23.30, a P/E/G ratio of 2.17 and a beta of 0.70.
Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.95 by $0.01. The business had revenue of $3.47 billion during the quarter, compared to analyst estimates of $3.42 billion. Stryker had a return on equity of 24.56% and a net margin of 8.20%. Stryker’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period last year, the company earned $1.78 earnings per share. analysts predict that Stryker Corporation will post 7.12 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, April 30th. Shareholders of record on Thursday, March 29th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 1.22%. The ex-dividend date is Wednesday, March 28th. Stryker’s payout ratio is 70.15%.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.